Soleno Therapeutics Q4 Financial Report Reveals -$0.33 GAAP EPS
Wednesday, 6 March 2024, 21:47
Soleno Therapeutics Financial Report Summary
Soleno Therapeutics recently reported its Q4 financial performance, with a GAAP EPS of -$0.33, falling short by $0.07. The company disclosed that it had cash and equivalents of $169.7 million as of December.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.